Market Place
Sourcing Support
PureTech`s Seaport Therapeutics Names CFO Lauren White
05 Nov 2024 //
BUSINESSWIRE
PureTech to Present at Two Upcoming Investor Conferences
30 Oct 2024 //
BUSINESSWIRE
PureTech’s Seaport Therapeutics Raises $225M In Series B Financing
21 Oct 2024 //
BUSINESSWIRE
PureTech Presents IPF Research And LYT-100 Analysis At CHEST
08 Oct 2024 //
BUSINESSWIRE
PureTech to Present at CHEST 2024 Annual Meeting
01 Oct 2024 //
BUSINESSWIRE
PureTech`s Vor Bio Announces New Clinical Data
06 Sep 2024 //
BUSINESSWIRE
PureTech Health plc – Half-Year Report
27 Aug 2024 //
BUSINESSWIRE
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
22 Aug 2024 //
BUSINESSWIRE
PureTech Health: Notice of Half-Yearly Results
20 Aug 2024 //
BUSINESSWIRE
PureTech`s Seaport Therapeutics Appoints David Wheadon To Board
13 Aug 2024 //
BUSINESSWIRE
PureTech Health: Results of the Tender Offer
24 Jun 2024 //
BUSINESSWIRE
PureTech Health completes tender offer and updates total voting rights.
24 Jun 2024 //
BUSINESSWIRE
PureTech Health: Results of Annual General Meeting
13 Jun 2024 //
BUSINESSWIRE
PureTech Health: Result of General Meeting
06 Jun 2024 //
BUSINESSWIRE
Akili, Virtual Therapeutics To Merge Into Digital Health Leader
29 May 2024 //
BUSINESSWIRE
PureTech to Present at the Jefferies Global Healthcare Conference
23 May 2024 //
BUSINESSWIRE
PureTech Health Launch of Proposed $100 million Tender Offer at 250
20 May 2024 //
PHARMIWEB
PureTech`s Seaport Adds Board Member, Executive Appointments
07 May 2024 //
BUSINESSWIRE
PureTech Announces Annual Results for Year Ended December 31, 2023
25 Apr 2024 //
BUSINESSWIRE
PureTech Completes LYT-100 IPF ELEVATE 2b Enrollment
16 Apr 2024 //
BUSINESSWIRE
PureTech Proposes $100 Million Capital Return
19 Mar 2024 //
BUSINESSWIRE
Akili Announces Positive Results from Shionogi’s Phase 3 Trial of EndeavorRx
27 Feb 2024 //
BUSINESSWIRE
PureTech to Present at Two Upcoming Investor Conferences
27 Feb 2024 //
BUSINESSWIRE
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
PureTech Year End Update and Outlook for 2024
19 Dec 2023 //
BUSINESSWIRE
PureTech Presents Data from Phase 1 Trial Targeting Galectin-9 in Solid Tumors
07 Dec 2023 //
BUSINESSWIRE
PureTech`s LYT-300 Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial
14 Nov 2023 //
BUSINESSWIRE
Q&A: PureTech CEO Daphne Zohar talks biotech interests on Capitol Hill
01 Nov 2023 //
ENDPTS
PureTech gives up on regaining control of Gelesis and its weight loss pill
17 Oct 2023 //
ENDPTS
PureTech Presents Data from LYT-100 Trial in Annual Meeting
11 Oct 2023 //
BUSINESSWIRE
Vedanta Bio Announces First Patient Dosed in Phase 2 Clinical Trial of VE202
04 Oct 2023 //
BUSINESSWIRE
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
27 Sep 2023 //
BUSINESSWIRE
PureTech Health: Notice of Half-Yearly Results
22 Aug 2023 //
BUSINESSWIRE
PureTech Awarded up to $11.4 Million from U.S. DoD to Advance LYT-300
01 Aug 2023 //
BUSINESSWIRE
PureTech Health snags $11.4M from DOD to test hormone drug in rare brain disease
01 Aug 2023 //
ENDPTS
PureTech begins phase 2a trial of LYT-300 for treatment of anxiety disorders
26 Jun 2023 //
PHARMABIZ
PureTech begins proof-of-concept study for anxiety treatment
22 Jun 2023 //
CLINICAL TRIALS ARENA
PureTech Initiates Phase 2a Clinical Trial of LYT-300
21 Jun 2023 //
BUSINESSWIRE
Results of PureTech`s Annual General Meeting
13 Jun 2023 //
BUSINESSWIRE
PureTech Founded Entity Vedanta Biosciences Receives FTD for VE303
09 May 2023 //
BUSINESSWIRE
PureTech Founded Entity Akili Announces Adults with ADHD
04 May 2023 //
BUSINESSWIRE
PureTech Announces Annual Results for Year Ended December 31, 2022
28 Apr 2023 //
BUSINESSWIRE
PureTech Founded Entity Vedanta Biosciences Announces $106.5 M Financing
25 Apr 2023 //
BUSINESSWIRE
PureTech Health: Notice of Results
13 Apr 2023 //
BUSINESSWIRE
PureTech wants to buy back its weight loss pill spinout after lackluster SPAC
05 Apr 2023 //
ENDPTS
PureTech and Royalty Enter into KarXT Royalty Agreement for up to $500 Million
23 Mar 2023 //
BUSINESSWIRE
PureTech to Present at the Barclays Global Healthcare Conference
01 Mar 2023 //
BUSINESSWIRE
PureTech to Advance LYT-300 for the Treatment of Anxiety Disorders
14 Feb 2023 //
BUSINESSWIRE
PureTech to Present at the SVB Securities Global Biopharma Conference
01 Feb 2023 //
BUSINESSWIRE
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability
19 Dec 2022 //
BUSINESSWIRE
PureTech readies oral CBD capsule for clinic to challenge Jazz
01 Dec 2022 //
FIERCEPHARMA
PureTech Announces New Therapeutic Candidate, LYT-310, Oral Form
30 Nov 2022 //
BUSINESSWIRE
PureTech to Present at Two Upcoming Investor Conferences
17 Nov 2022 //
BUSINESSWIRE
PureTech to Present at the Jefferies London Healthcare Conference
09 Nov 2022 //
BUSINESSWIRE
PureTech Founded Entity Gelesis Announces Two Presentations at ObesityWeek 2022
02 Nov 2022 //
PRESS RELEASE
PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
01 Nov 2022 //
BUSINESSWIRE
UPDATE: Record scratch—Nektar and PureTech`s merger talks are off
11 Oct 2022 //
FIERCEBIOTECH
PureTech confirms negotiations for a possible Nektar merger
09 Oct 2022 //
PHARMAPHORUM
Nektar`s plans to buy PureTech confirmed
08 Oct 2022 //
FIERCEBIOTECH
PureTech Presents Data for LYT-100 at ERSI Congress 2022
06 Sep 2022 //
BUSINESSWIRE
